Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
287 Leser
Artikel bewerten:
(1)

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

DJ Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. ( irsh) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 24-March-2023 / 12:08 GMT/BST

-----------------------------------------------------------------------------------------------------------------------

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

a.     Full name of discloser                          The Vanguard 
                                                    Group, Inc. 
 b.     Owner or controller of interests and short positions disclosed, if different 
  from 1(a) 
 
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and 
beneficiaries must be named. 
 c.     Name of offeror/offeree in relation to whose relevant securities this form 
  relates                                          Horizon 
                                                    Therapeutics plc 
Use a separate form for each offeror/offeree 
 d.     If an exempt fund manager connected with an offeror/offeree, state this and 
  specify identity of offeror/offeree (Note 1) 
 e.     Date position held/dealing undertaken 
                                                    22 March 2023 
For an opening position disclosure, state the latest practicable date prior to the disclosure 
 f.      In addition to the company in 1(c) above, is the discloser also making 
  disclosures in respect of any other party to the offer?                  N/A 
If it is a cash offer or possible cash offer, state "N/A" 

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security                                USUSD0.0001 ordinary shares 
(Note 3) 
                                             Interests    Short 
                                                     positions 
                                             Number   %   Number   % 
 1. Relevant securities owned and/or controlled            21,524,286 9.41% 
 2. Cash-settled derivatives 
 3. Stock-settled derivatives (including options) and agreements to purchase/ 
  sell 
Total                                          21,524,286 9.41% 

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1 (c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Purchase/sale           Price per unit 
Class of relevant security        Number of securities (Note 5) 
 
USUSD0.0001 ordinary shares Purchase   3,022        107.32 USD 
USUSD0.0001 ordinary shares Sale     1,912        107.32 USD 

Ap29

(b) Cash-settled derivative transactions

Number of Price 
Class of   Product   Nature of dealing                             reference per 
relevant   description e.g. opening/ closing a long/ short position, increasing/ reducing a long/ securities unit 
security   e.g. CFD  short position                               (Note 6)  (Note 
                                                        5) 
 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Number 
       Product                       of     Exercise Type       Option 
Class of   description e.g.  Writing, purchasing, selling,   securities price  e.g.   Expiry money 
relevant   call        varying              to which  per   American, date  paid/ 
security   option       etc.               option   unit   European     received per 
                                  relates       etc.       unit 
                                  (Note 6) 
 

(ii) Exercise

Class of    Product   Exercising/      Exercise 
relevant    description exercised  Number of price per 
security    e.g. call  against   securities unit 
        option               (Note 5) 
 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of    Nature of dealing       Price per unit (if 
relevant    e.g. subscription,  Details applicable) 
security    conversion, exercise     (Note 5) 
 Not Applicable 

Ap30

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to 
relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the 
disclosure and any party to the offer or any person acting in concert with a party to the offer. 
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or 
understandings, state "none" 
 none 

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 none 

(c) Attachments

Is a Supplemental Form 8 attached? No 
Date of disclosure 24 March 2023 
Contact name    Shawn Acker 
Telephone number  001-610-669-6713 

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Category Code: RET - Horizon Therapeutics plc 
TIDM:     irsh 
LEI Code:   5493002789CX3L0CJP65 
Sequence No.: 232537 
EQS News ID:  1592069 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1592069&application_name=news

(END) Dow Jones Newswires

March 24, 2023 08:09 ET (12:09 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2023 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.